Compare BNTC & PNNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BNTC | PNNT |
|---|---|---|
| Founded | 1995 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 411.4M | 397.7M |
| IPO Year | 2020 | 2007 |
| Metric | BNTC | PNNT |
|---|---|---|
| Price | $10.91 | $4.53 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 5 |
| Target Price | ★ $27.67 | $5.85 |
| AVG Volume (30 Days) | 161.7K | ★ 728.5K |
| Earning Date | 05-13-2026 | 05-11-2026 |
| Dividend Yield | N/A | ★ 21.29% |
| EPS Growth | ★ 80.94 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $13.14 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.85 | $4.51 |
| 52 Week High | $17.15 | $7.53 |
| Indicator | BNTC | PNNT |
|---|---|---|
| Relative Strength Index (RSI) | 42.12 | 33.17 |
| Support Level | $10.10 | N/A |
| Resistance Level | $12.91 | $4.93 |
| Average True Range (ATR) | 0.71 | 0.15 |
| MACD | -0.10 | 0.00 |
| Stochastic Oscillator | 9.33 | 3.33 |
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.
Pennant Park Investment Corp is a closed-end, non-diversified investment company. Its investment objective is to generate current income and capital appreciation also seeking to preserve capital through debt and equity investments. The company focuses on investing in United States middle-market companies that offer attractive risk-reward to investors and to create a diversified portfolio that includes senior secured debt, mezzanine debt, and equity investments. It generates majority of its revenue from interest and dividends received from investments made.